Cancer Stem Cell News
Pancreatic Cell News
Pancreatic Cell News is an online resource providing updates on the latest pancreatitis, diabetes, and pancreatic cancer research.
Subscribe|Follow Us On
Sequential Dual Nanoparticle Approach for Extracellular Matrix Remodeling and Targeted Chemotherapy through Liposome-Exosome Hybridization in Pancreatic Cancer
[ACS Applied Materials & Interfaces] Researchers reported a sequential dual-nanoparticle approach that integrates ECM remodeling with tumor-targeted chemotherapy to overcome the insufficient tumor targeting and poor intratumoral penetration of liposomal doxorubicin.
Glucose Controls Metallothionein 1 Gene Expression in Pancreatic Islets via a Mechanism Involving Cellular Metabolism, Granular Zinc, and the Zinc Transporter ZnT8 in Rat and...
[Diabetologia] Researchers examined whether physiological changes in blood glucose levels in vivo control islet metallothionein 1 gene expression similarly to ex vivo observations, and identify the mechanisms involved.
Design of Short-Sequenced Collagen Type III-Derived Peptides with GPR56 Dependent Biological Activity
[Bioscience Reports] The activation of GPR56 by its endogenous ligand Coll III improves pancreatic β-cell function. Scientists, through the alignment of collagen type III (Coll III) and G protein-coupled receptor 56 (GPR56) genomic DNA, revealed three complementary nucleotide regions, enabling the design of three short peptides.
Octreotide Attenuates Pancreatic Fibrosis through Modulation of the HMGB1-Wnt/β-Catenin Axis in Experimental Chronic Pancreatitis
[Molecular and Cellular Biochemistry] Investigators aimed to determine whether octreotide attenuates dibutyltin dichloride-induced pancreatic fibrosis through suppression of high-mobility group box 1 (HMGB1) and downstream Wnt/β-catenin signaling.
Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression
[Nature Genetics] To understand how heterogeneity contributes to PDAC biology, researchers analyzed a large cohort of primary tumors profiled using single-cell RNA sequencing to map clonal, transcriptional and spatial diversity.
Sequential Dual Nanoparticle Approach for Extracellular Matrix Remodeling and Targeted Chemotherapy through Liposome-Exosome Hybridization in Pancreatic Cancer
[ACS Applied Materials & Interfaces] Scientists reported a sequential dual-nanoparticle approach that integrates extracellular matrix remodeling with tumor-targeted chemotherapy to overcome barriers in liposomal doxorubicin formulations for pancreatic cancer.
Optimization and Mechanistic Characterization of a Selective Benzoxazine-Based MAP4K4 Inhibitor in Pancreatic Cancer Cells
[Journal of Enzyme Inhibition and Medicinal Chemistry] Researchers used the scaffold of F389-0746, a selective benzoxazine-based MAP4K4 inhibitor with anti-cancer activity in pancreatic cancer, to guide the selection and evaluation of benzoxazine-based analogs, followed by biochemical, structural, selectivity, and cellular characterization of the most potent analogue.
Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers
[Current Oncology Reports] Investigators provide a critical narrative synthesis of Actinomycetota-derived metabolites evaluated in pancreatic cancer models, with every potency value re-derived from the primary literature and interpreted alongside assay conditions and available mechanistic and in vivo evidence.
Revisiting Chronic Pancreatitis as a Risk Factor for Pancreatic Ductal Adenocarcinoma: Toward Precision Risk Stratification
[Expert Review of Gastroenterology & Hepatology] The authors critically review epidemiological, mechanistic, and causal evidence linking chronic pancreatitis (CP) with PDAC, focusing on heterogeneity across CP subtypes and disease trajectories.
Targeting RAS in Pancreatic Cancer
[Cancer] The authors synthesize RAS biology, molecular-testing implications, clinical efficacy and toxicity data, and ongoing phase II and phase III trials for PDAC.
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
[Medicovestor, Inc. (Globe Newswire)] Medicovestor, Inc. announced that the US FDA has granted Fast Track designation to MC001, its lead investigational first-in-class chemoimmunotherapy antibody-drug-conjugate (ADC) for pancreatic cancer.
UToledo Researcher Receives Ohio Cancer Research Grant to Study Pancreatic Cancer’s Resistance to Treatment
[The University of Toledo] Dr. Kuo-Hui Su, assistant professor in the Department of Cell and Cancer Biology at the University of Toledo, has been awarded a two-year, $80,000 grant from Ohio Cancer Research to investigate a potential new approach to treating pancreatic cancer — one that targets the disease’s ability to resist the treatments designed to fight it.
Pancreatic Cell News highlights recent top articles in the field of pancreatic cell research. These articles have been carefully selected from high-impact, peer-reviewed academic journals by our experienced editorial team. We cover topics including pancreatic cell culture, pancreatitis, diabetes, and pancreatic cancer. We also feature the latest industry and policy news alongside job postings and upcoming events to keep scientists current while saving them valuable time.
